⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL886935 | 0.70 | ALDH1A1 (0.50) | — | |
| SCHEMBL23343471 | 0.69 | — | — | |
| SCHEMBL386081 | 0.69 | — | — | |
| SCHEMBL29275136 | 0.69 | ALDH1A1 (0.59) | — | |
| SCHEMBL31852 | 0.69 | — | — | |
| SCHEMBL2633010 | 0.69 | — | — | |
| SCHEMBL12279311 | 0.69 | — | — | |
| SCHEMBL7074849 | 0.69 | — | — | |
| SCHEMBL2966799 | 0.69 | — | — | |
| SCHEMBL27977830 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973164-B2 | Quinoline derivatives | ASTRAZENECA AB (SE) | 2011-07-05 | — | — | US | claimed |
| US-20090233950-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | claimed |
| CN-101437811-A | Quinoline derivatives | ASTRAZENECA AB (SE) | 2009-05-20 | — | — | CN | claimed |
| CN-101437810-A | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-05-20 | — | — | CN | claimed |
| CN-101437812-A | Quinoline derivatives for the treatment of cancer | ASTRAZENECA AB (SE) | 2009-05-20 | — | — | CN | claimed |
| CN-101432276-A | Quinoline derivatives | ASTRAZENECA AB (SE) | 2009-05-13 | — | — | CN | claimed |
| US-20090076075-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | claimed |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | claimed |
| US-20090042910-A1 | QUINOLINE DERIVATIVES FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | claimed |
| EP-1994024-A2 | QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | claimed |
| EP-1994023-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | claimed |
| EP-1994028-A1 | QUINOLINE DERIVATIVES FOR TREATING CANCER | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | claimed |
| EP-1994025-A1 | QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | claimed |
| WO-2007113565-A1 | NAPHTHYRIDINE DERIVATIVES AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | claimed |
| WO-2007113548-A1 | NAPHTHYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | claimed |
| WO-2007099323-A2 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | claimed |
| WO-2007099317-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | claimed |
| WO-2007099335-A1 | QUINOLINE DERIVATIVES FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | claimed |
| WO-2007099326-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | claimed |
| WO-2023032729-A1 | BINDER FOR NON-AQUEOUS SECONDARY BATTERY SEPARATOR, RESIN COMPOSITION FOR NON-AQUEOUS SECONDARY BATTERY SEPARATOR, NON-AQUEOUS SECONDARY BATTERY SEPARATOR, NON-AQUEOUS SECONDARY BATTERY, POWER STORAGE DEVICE AND BINDER USED THEREIN, AQUEOUS DISPERSION, RESIN COMPOSITION, SEPARATOR&LT; AND BINDER PRODUCTION METHOD | 東洋インキＳＣホールディングス株式会社 | 2023-03-09 | — | — | WO | disclosed |
| US-20210088524-A1 | IMAGING AGENT | UNIVERSITY OF LANCASTER (GB) | 2021-03-25 | — | — | US | disclosed |
| CN-108026100-B | Substituted 1, 2-dihydro-3H-pyrrolo [1,2-c ] imidazol-3-one antibacterial agents | 爱杜西亚药品有限公司 | 2020-09-18 | — | — | CN | disclosed |
| US-10441576-B2 | Substituted 1,2-dihydro-3H pyrrolo[1,2-c]imidazol-3 one antibacterials | IDORSIA PHARMACEUTICALS LTD. (CH) | 2019-10-15 | — | — | US | disclosed |
| EP-3334737-B1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-10-09 | — | — | EP | disclosed |
| EP-3535255-A1 | PYRIDAZINE DERIVATIVES AS RORC MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2019-09-11 | — | — | EP | disclosed |
| WO-2019162308-A1 | BENZAMIDE COMPOUNDS AND THEIR USE AS HERBICIDES | BASF SE (DE) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019162309-A1 | BENZAMIDE COMPOUNDS AND THEIR USE AS HERBICIDES | BASF SE (DE) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019016385-A1 | BENZAMIDE COMPOUNDS AND THEIR USE AS HERBICIDES | BASF SE (DE) | 2019-01-24 | — | — | WO | disclosed |
| WO-2018234371-A1 | BENZAMIDE COMPOUNDS AND THEIR USE AS HERBICIDES | BASF SE (DE) | 2018-12-27 | — | — | WO | disclosed |
| WO-2018185493-A1 | IMAGING AGENT | UNIVERSITY OF LANCASTER (GB) | 2018-10-11 | — | — | WO | disclosed |
| US-20180235938-A1 | SUBSTITUTED 1,2-DIHYDRO-3H PYRROLO[1,2-c]IMIDAZOL-3 ONE ANTIBACTERIALS | IDORSIA PHARMACEUTICALS LTD. (CH) | 2018-08-23 | — | — | US | disclosed |
| US-20180199575-A1 | SUBSTITUTED OXOTETRAHYDROQUINOLINYLPHOSPHINIC ACID AND PHOSPHINIC ACID AMIDES OR SALTS THEREOF AND USE THEREOF TO INCREASE STRESS TOLERANCE IN PLANTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-07-19 | — | — | US | disclosed |
| EP-3334737-A1 | SUBSTITUTED 1,2-DIHYDRO-3H | Idorsia Pharmaceuticals Ltd (CH) | 2018-06-20 | — | — | EP | disclosed |
| EP-3322296-A1 | SUBSTITUTED OXO-TETRAHYDROQUINOLINYL-PHOSPHINIC ACID AND PHOSPHINIC ACID AMIDES OR SALTS THEREOF AND USE THEREOF TO INCREASE STRESS TOLERANCE IN PLANTS | Bayer CropScience Aktiengesellschaft (DE) | 2018-05-23 | — | — | EP | disclosed |
| EP-3319962-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2018-05-16 | — | — | EP | disclosed |
| EP-3292108-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2018-03-14 | — | — | EP | disclosed |
| EP-3292117-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2018-03-14 | — | — | EP | disclosed |
| EP-3292111-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2018-03-14 | — | — | EP | disclosed |
| EP-3233849-A1 | HETEROARYLALKYLENE ARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| WO-2017025562-A1 | SUBSTITUTED 1,2-DIHYDRO-3H PYRROLO[1,2-c]IMIDAZOL-3 ONE ANTIBACTERIALS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-02-16 | — | — | WO | disclosed |
| EP-3128841-A1 | USE OF SUBSTITUTED OXO TETRAHYDROQUINOLINE SULFONAMIDES OR SALTS THEREOF FOR RAISING STRESS TOLERANCE OF PLANTS | Bayer CropScience Aktiengesellschaft (DE) | 2017-02-15 | — | — | EP | disclosed |
| US-20170027172-A1 | USE OF SUBSTITUTE OXO TETRAHYDROQUINOLINE SULFONAMIDES OR SALTS THEREOF FOR RAISING STRESS TOLERANCE OF PLANTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-02-02 | — | — | US | disclosed |
| WO-2017009321-A1 | SUBSTITUTED OXO-TETRAHYDROQUINOLINYL-PHOSPHINIC ACID AND PHOSPHINIC ACID AMIDES OR SALTS THEREOF AND USE THEREOF TO INCREASE STRESS TOLERANCE IN PLANTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-01-19 | — | — | WO | disclosed |
| WO-2017005668-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-01-12 | — | — | WO | disclosed |
| WO-2017005900-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-01-12 | — | — | WO | disclosed |
| EP-3092237-A1 | HETEROARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. Hoffmann-La Roche AG (CH) | 2016-11-16 | — | — | EP | disclosed |
| EP-3092239-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. Hoffmann-La Roche AG (CH) | 2016-11-16 | — | — | EP | disclosed |
| WO-2016177686-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-11-10 | — | — | WO | disclosed |
| WO-2016177760-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-11-10 | — | — | WO | disclosed |
| WO-2016177710-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-11-10 | — | — | WO | disclosed |
| EP-3066082-A1 | 5,6,7,8-TETRAHYDRO-5,8-METHANOCINNOLINE DERIVATIVES AS RORC MODULATORS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | F. Hoffmann-La Roche AG (CH) | 2016-09-14 | — | — | EP | disclosed |
| WO-2016096936-A1 | HETEROARYLALKYLENE ARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-23 | — | — | WO | disclosed |
| WO-2015155154-A1 | USE OF SUBSTITUTED OXO TETRAHYDROQUINOLINE SULFONAMIDES OR SALTS THEREOF FOR RAISING STRESS TOLERANCE OF PLANTS | BAYER CROPSCIENCE AG (DE) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015104354-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015104353-A1 | HETEROARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015067575-A1 | 5,6,7,8-TETRAHYDRO-5,8-METHANOCINNOLINE DERIVATIVES AS RORC MODULATORS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-05-14 | — | — | WO | disclosed |
| CN-101072758-B | Quinazoline derivatives | ASTRAZENECA AB | 2013-07-31 | — | — | CN | disclosed |
| EP-2593457-A1 | PYRAZOLO [1, 5A]PYRIMIDINE AND THIENO [3, 2B]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| EP-2480545-A1 | FUSED TRIAZOLE AMINES AS P2X7 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| US-20120165351-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| EP-2459541-A1 | DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-06-06 | — | — | EP | disclosed |
| US-8153643-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| WO-2012007375-A1 | PYRAZOLO [1, 5A] PYRIMIDINE AND THIENO [3, 2B] PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| EP-2396314-A1 | PROCESS FOR PREPARATION OF BEZOYL AMINO HETEROCYCLYL COMPOUNDS | AstraZeneca AB (SE) | 2011-12-21 | — | — | EP | disclosed |
| US-8076481-B2 | Chemical process 632 | ASTRAZENECA AB (SE) | 2011-12-13 | — | — | US | disclosed |
| US-7977328-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-07-12 | — | — | US | disclosed |
| WO-2011080755-A1 | FUSED NITROGEN HETEROCYCLIC COMPOUNDS, PROCESS OF PREPARATION AND USES THEREOF | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2011-07-07 | — | — | WO | disclosed |
| US-7973164-B2 | Quinoline derivatives | ASTRAZENECA AB (SE) | 2011-07-05 | — | — | US | disclosed |
| US-7964725-B2 | Heteroarylbenzamide derivatives for use in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| EP-2324028-A2 | THERAPEUTIC AGENTS 414 | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| US-7943607-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| EP-2305674-A1 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| EP-2301929-A1 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | AstraZeneca AB (Publ) (SE) | 2011-03-30 | — | — | EP | disclosed |
| EP-2301935-A1 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | AstraZeneca AB (Publ) (SE) | 2011-03-30 | — | — | EP | disclosed |
| WO-2011033055-A1 | FUSED TRIAZOLE AMINES AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-24 | — | — | WO | disclosed |
| US-20110059941-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B] PYRIDINE/PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| US-7902200-B2 | 3-[6-(Azetidine-1-carbonyl)pyridin-3-yl]oxy-5-[(3S)-1-methyl-2-oxo-pyrrolidin-3-yl]oxy-N-(5-methylpyrazin-2-yl)benzamide; activates glucokinase leading to decreased glucose threshold for insulin secretion and lowering of blood glucose by increasing hepatic glucose uptake; antidiabetic agents; obesity | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-20110053910-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | ASTRAZENECA AB (SE) | 2011-03-03 | — | — | US | disclosed |
| US-20110034432-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS | ASTRAZENECA AB (SE) | 2011-02-10 | — | — | US | disclosed |
| WO-2011012592-A1 | DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-03 | — | — | WO | disclosed |
| EP-2272834-A1 | Benzoyl amino heterocyclyl compounds as glucokinase (GLK) activators | AstraZeneca AB (SE) | 2011-01-12 | — | — | EP | disclosed |
| US-7842694-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2010-11-30 | — | — | US | disclosed |
| EP-2234989-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND/OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-20100210841-A1 | CHEMICAL PROCESS 632 | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| WO-2010092387-A1 | PROCESS FOR PREPARATION OF BEZOYL AMINO HETEROCYCLYL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | WO | disclosed |
| EP-1756076-B1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2010-08-11 | — | — | EP | disclosed |
| US-20100173825-A1 | HETEROARYL BENZAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| US-7745475-B2 | Such as 3-[(1S)-2-hydroxy-1-methylethoxy]-5-[4-(methylsulfonyl)phenoxy]-N-1,3-thiazol-2-ylbenzamide; glucokinases (Glk) | ASTRAZENECA AB (SE) | 2010-06-29 | — | — | US | disclosed |
| US-20100160286-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES | ASTRAZENECA UK LIMITED AB (SE) | 2010-06-24 | — | — | US | disclosed |
| US-7700640-B2 | Process for making phenoxy benzamide compounds | ASTRAZENECA AB (SE) | 2010-04-20 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| US-7671060-B2 | Heteroaryl benzamide derivatives | ASTRAZENECA AB (SE) | 2010-03-02 | — | — | US | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
| US-7642259-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2010-01-05 | — | — | US | disclosed |
| US-7642263-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2010-01-05 | — | — | US | disclosed |
| US-20090264336-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
| US-20090253676-A1 | Heteroaryl Benzamide Derivatives for Use as GLK Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2009-10-08 | — | — | US | disclosed |
| US-20090233950-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| US-20090233924-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| EP-2086964-A2 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK | Astra Zeneca AB (SE) | 2009-08-12 | — | — | EP | disclosed |
| EP-2078000-A1 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS AS GLUCOKINASE (GLK) ACTIVATORS | AstraZeneca AB (SE) | 2009-07-15 | — | — | EP | disclosed |
| WO-2009077371-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND/OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| CN-101437810-A | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-05-20 | — | — | CN | disclosed |
| CN-101437812-A | Quinoline derivatives for the treatment of cancer | ASTRAZENECA AB (SE) | 2009-05-20 | — | — | CN | disclosed |
| CN-101437811-A | Quinoline derivatives | ASTRAZENECA AB (SE) | 2009-05-20 | — | — | CN | disclosed |
| CN-101432276-A | Quinoline derivatives | ASTRAZENECA AB (SE) | 2009-05-13 | — | — | CN | disclosed |
| US-20090118159-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-20090111790-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090105214-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105263-A1 | HETEROBICYCLIC COMPOUNDS AS GLUCOKINASE ACTIVATORS | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| EP-2048137-A1 | Benzamide derivatives and their use as glucokinase activating agents. | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| EP-1718624-B1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS | ASTRAZENECA AB (SE) | 2009-03-25 | — | — | EP | disclosed |
| US-20090076075-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| EP-2027113-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2009-02-25 | — | — | EP | disclosed |
| US-20090042910-A1 | QUINOLINE DERIVATIVES FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | disclosed |
| US-20090036485-A1 | Quinoline derivatives | JUNG FREDERIC HENRI | 2009-02-05 | — | — | US | disclosed |
| US-20090029905-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| US-20080318968-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080312207-A1 | Compounds | SYNGENTA CROP PROTECTION AG (CH) | 2008-12-18 | — | — | US | disclosed |
| EP-1994024-A2 | QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| EP-1994023-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| EP-1994028-A1 | QUINOLINE DERIVATIVES FOR TREATING CANCER | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| EP-1994025-A1 | QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| EP-1992623-A1 | Heteroaryl benzamide derivative for use as GLK activator in the treatment of diabetes | Astra Zeneca AB (SE) | 2008-11-19 | — | — | EP | disclosed |
| US-20080280872-A1 | Benzamide Derivatives and Their Use as Glucokinase Activating Agents | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
| US-20080280874-A1 | Phenoxy Benzamide Compounds with Utility in the Treatment of Type 2 Diabetes and Obesity | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
| US-20080234273-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | US | disclosed |
| US-20080200694-A1 | Process for Making Phenoxy Benzamide Compounds | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| US-20080171734-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| EP-1928874-A1 | HETEROBICYCLIC COMPOUNDS AS GLUCOKINASE ACTIVATORS | AstraZeneca AB (SE) | 2008-06-11 | — | — | EP | disclosed |
| WO-2008050117-A1 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS AS GLUCOKINASE (GLK) ACTIVATORS | ASTRAZENECA AB (SE) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008050101-A2 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK | ASTRAZENECA AB (SE) | 2008-05-02 | — | — | WO | disclosed |
| EP-1915367-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| EP-1910350-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| EP-1902052-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| EP-1891069-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B]PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| EP-1891058-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| US-20080015203-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-20070287693-A1 | Benzamide Derivatives That Act Upon The Glucokinase Enzyme | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | US | disclosed |
| EP-1856056-A1 | PHENOXY BENZAMIDE COMPOUNDS WITH UTILITY IN THE TREATMENT OF TYPE 2 DIABETES AND OBESITY | AstraZeneca AB (SE) | 2007-11-21 | — | — | EP | disclosed |
| CN-101072758-A | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2007-11-14 | — | — | CN | disclosed |
| WO-2007113565-A1 | NAPHTHYRIDINE DERIVATIVES AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113548-A1 | NAPHTHYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007099323-A2 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007099317-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007099326-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007099335-A1 | QUINOLINE DERIVATIVES FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | disclosed |
| EP-1802608-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| EP-1802603-A1 | QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| EP-1802591-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| EP-1802570-A1 | PROCESS FOR MAKING PHENOXY BENZAMIDE COMPOUNDS | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| EP-1802582-A1 | BENZAMIDE DERIVATIVES THAT ACT UPON THE GLUCOKINASE ENZYME. | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2007031739-A1 | HETEROBICYCLIC COMPOUNDS AS GLUCOKINASE ACTIVATORS | ASTRAZENECA AB (SE) | 2007-03-22 | — | — | WO | disclosed |
| EP-1756076-A1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2007017649-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
| EP-1745002-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2007-01-24 | — | — | EP | disclosed |
| WO-2007007041-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007007040-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007007042-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006125958-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4 , 5B] PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006125972-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
| EP-1718624-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS | AstraZeneca AB (SE) | 2006-11-08 | — | — | EP | disclosed |
| EP-1718625-A1 | COMPOUNDS | AstraZeneca AB (SE) | 2006-11-08 | — | — | EP | disclosed |
| WO-2006040527-A1 | PROCESS FOR MAKING PHENOXY BENZAMIDE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006040529-A1 | BENZAMIDE DERIVATIVES THAT ACT UPON THE GLUCOKINASE ENZYME | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006040528-A1 | PHENOXY BENZAMIDE COMPOUNDS WITH UTILITY IN THE TREATMENT OF TYPE 2 DIABETES AND OBESITY | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006040520-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006040522-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006040526-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2005121110-A1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005105725-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005080360-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005080359-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINAE ACTIVATING AGENTS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
| US-5478825-A | Cardiotonic, antianginal agents | EGIS GYOGYSZERGYAR (HU) | 1995-12-26 | — | — | US | disclosed |
| US-5478825-A | Cardiotonic, antianginal agents | EGIS GYOGYSZERGYAR (HU) | 1995-12-26 | — | — | US | disclosed |